Literature DB >> 16436456

Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer.

Shipra Agrawal1, Charis Eng.   

Abstract

PTEN, a dual-phosphatase tumor suppressor, is inactivated in Cowden syndrome (CS), characterized by high risk of breast and thyroid cancer, and in variety of sporadic cancers. Despite the importance of alternative splicing, very limited information on its role in PTEN and associated cancers is available. We identified eight novel PTEN splice variants (SVs) that retained intron 3 regions (3a, 3b, 3c); intron 5 regions (5a, 5b, 5c); excluded part of exon 5 (DelE5) or all of exon 6 (DelE6), respectively. Analysis of SVs in 12 sporadic breast cancers revealed full-length (FL)-PTEN transcript reduction in 10; SVs 3b, 3c and 5c not expressed in 7, 6 and 4, respectively, and under-expressed in the rest. In contrast, SV-5b was over-expressed in breast cancers. PTEN SV analysis in 16 CS/CS-like patients and eight controls revealed that SV-5a is under-expressed and SV-3a over-expressed in the germline of CS/CS-like individuals when compared with controls. Although SV-5a expression decreased P-Akt level and cyclin D1 promoter activity, SVs 5b and 5c increased cyclin D1 promoter activity. Thus, SV-5a behaving like FL-PTEN corroborates our observation that SV-5a is under-expressed in CS when compared with controls. Similarly, SV-5b functionally counters PTEN's action and is over-expressed in sporadic breast cancers. Furthermore, we demonstrate that expression of these SVs is under the regulation of p53. Our observations suggest that differential expression of PTEN and its SVs could play a role in the pathogenesis of sporadic breast cancers and CS, and may lend a novel way of making a rapid molecular diagnosis of CS without mutation analysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436456     DOI: 10.1093/hmg/ddi492

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  27 in total

Review 1.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

Review 2.  Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.

Authors:  A Sveen; S Kilpinen; A Ruusulehto; R A Lothe; R I Skotheim
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

3.  Multiple metachronous malignancies, one patient with three primary malignancies.

Authors:  Sangeetha Jayaraman; Somesh Balakrishnan; Devaji Rao
Journal:  Indian J Surg       Date:  2011-04-27       Impact factor: 0.656

4.  Distinct expression profiles for PTEN transcript and its splice variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome.

Authors:  Marta S Sarquis; Shipra Agrawal; Lei Shen; Robert Pilarski; Xiao-Ping Zhou; Charis Eng
Journal:  Am J Hum Genet       Date:  2006-05-22       Impact factor: 11.025

Review 5.  PTEN proteoforms in biology and disease.

Authors:  Prerna Malaney; Vladimir N Uversky; Vrushank Davé
Journal:  Cell Mol Life Sci       Date:  2017-03-13       Impact factor: 9.261

6.  Aberrant RNA Splicing in Cancer.

Authors:  Luisa Escobar-Hoyos; Katherine Knorr; Omar Abdel-Wahab
Journal:  Annu Rev Cancer Biol       Date:  2018-11-28

Review 7.  PTEN hamartoma tumor syndromes.

Authors:  Gideon M Blumenthal; Phillip A Dennis
Journal:  Eur J Hum Genet       Date:  2008-09-10       Impact factor: 4.246

8.  Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

Authors:  L S Steelman; P M Navolanic; M L Sokolosky; J R Taylor; B D Lehmann; W H Chappell; S L Abrams; E W T Wong; K M Stadelman; D M Terrian; N R Leslie; A M Martelli; F Stivala; M Libra; R A Franklin; J A McCubrey
Journal:  Oncogene       Date:  2008-03-10       Impact factor: 9.867

9.  Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers.

Authors:  K L Lachlan; A M Lucassen; D Bunyan; I K Temple
Journal:  J Med Genet       Date:  2007-05-25       Impact factor: 6.318

10.  Clustering of sebaceous gland carcinoma, papillary thyroid carcinoma and breast cancer in a woman as a new cancer susceptibility disorder: a case report.

Authors:  Brian D Newman; Joseph F Maher; Jose S Subauste; Gabriel I Uwaifo; Steven A Bigler; Christian A Koch
Journal:  J Med Case Rep       Date:  2009-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.